Total antibody quantification for MMAE-conjugated antibody-drug conjugates: Impact of assay format and reagents

Bioconjugate Chemistry

Volumn 24, Issue 5, 2013, Pages 772-779

  Kozak, Katherine R ^a   Tsai, Siao Ping ^a   Fourie O'Donohue, Aimee ^a   Dela Cruz Chuh, Josefa ^a   Roth, Leslie ^a   Cook, Ryan ^a   Chan, Elton ^a   Chan, Pamela ^a   Darwish, Martine ^a   Ohri, Rachana ^a   Raab, Helga ^a   Zhang, Crystal ^a   Lin, Kedan ^a   Wong, Wai Lee T ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CHEMICAL DETECTION; CYTOTOXICITY; MONOCLONAL ANTIBODIES; PURIFICATION;

ANTI-CANCER AGENTS; ANTIBODY-DRUG CONJUGATES; CYTOTOXIC DRUGS; EXPECTED VALUES; HETEROGENEOUS MIXTURES; PHARMACOKINETIC STUDIES; QUANTITATIVE ASSAY; SAFETY STUDIES; THERAPEUTIC ANTIBODIES; TUBULIN POLYMERIZATION;

ASSAYS;

ANTIBODY CONJUGATE; CYTOTOXIC AGENT; VEDOTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY STRUCTURE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOASSAY; MOUSE; NONHUMAN;

EID: 84877791439     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc300491k     Document Type: Article

References (25)

1. Polakis, P. (2005) Arming antibodies for cancer therapy Curr. Opin. Pharmacol. 5, 382-387
2. Teicher, B. A. (2009) Antibody-drug conjugate targets Curr. Cancer Drug Target 9, 982-1004
3. Katz, J., Janik, J. E., and Younes, A. (2011) Brentuximab vedotin (SGN-35) Clin. Cancer Res. 17, 6428-6436
4. Beck, A., Senter, P., and Chari, R. (2011) World antibody drug conjugate summit Europe mAbs 3, 331-337
5. Teicher, B. A. and Chari, R. V. J. (2011) Antibody conjugate therapeutics: Challenges and potential Clin. Cancer Res. 17, 6389-6397
6. Bai, R. L., Pettit, G. R., and Hamel, E. (1990) Structure-activity studies with chiral isomers and with segments of the anti-mitotic marine peptide dolastatin 10 Biochem. Pharmacol. 40, 1859-1864
7. Francisco, J. A., Cerveny, C. G., Meyer, D. L., Mixan, B. J., Klussman, K., Chace, D. F., Rejniak, S. X., Gordon, K. A., DeBlanc, R., Toki, B. E., Law, C. L., Doronina, S. O., Siegall, C. B., Senter, P. D., and Wahl, A. F. (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity Blood 102, 1458-1465
8. Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., Francisco, J. A., Wahl, A. F., Meyer, D. L., and Senter, P. D. (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy Nat. Biotechnol. 21, 778-784
9. Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., Meyer, D. L., and Francisco, J. A. (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate Clin. Cancer Res. 10, 7063-7070
10. Engvall, E. and Perlman, P. (1971) Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G Immunochemistry 8, 871-874
11. Lequin, R. M. (2005) Enzyme immunoassay (EIA)/ enzyme-linked immunosorbent assay (ELISA) Clin. Chem. 51, 2415-2418
12. Sanderson, R. J., Hering, M. A., James, S. F., Sun, M. M. C., Doronina, O., Siadak, A. W., Senter, P. D., and Wahl, A. F. (2005) In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate Clin. Cancer Res. 11, 843-852
13. McDonagh, C. F., Turcott, E., Westerndorf, L., Webster, J. B., Alley, S. C., Kim, K., Andreyka, J., Stone, I., Hamblett, K.J., Francsco, J. A., and Carter, P. (2006) Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment Protein Eng., Des. Sel. 19, 299-307
14. Pollack, V. A., Alvarez, E., Tse, K. F., Torgov, M. Y., Xie, S., Shenoy, S. G., MacDougall, J. R., Arrol, S., Zhong, H., Gerwien, R. W., Hahne, W. F., Senter, P. D., Jeffers, M. E., Lichenstein, H. S., and LaRochelle, W. J. (2007) Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB Cancer Chemother. Pharmacol. 60, 423-435
15. Hwu, P., Sznol, M., Pavlick, A., Kluger, H., Rink, L., Kim, K. B., Papadopoulos, N. E., Sanders, D., Boasberg, P., Ooi, C. E., and Hamid, O. (2008) A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate, in patients with unresectable stage III or stage IV melanoma ASCO Meeting Abstracts 2008, 9029
16. Kim, K. M., McDonagh, C. F., Westendorf, L., Brown, L. L., Sussman, D., Feist, T., Lyon, R., Alley, S. C., Okeley, N. M., Zhang, X., Thompson, M. C., Stone, I., Gerber, H. P., and Carter, P. J. (2008) Anti-CD30 diabody-drug conjugates with potent antitumor activity Mol. Cancer Ther. 7, 2486-2497
17. Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., Lu, Y., Meng, Y. G., Ng, C., Yang, J., Lee, C. C., Duenas, E., Gorrell, J., Katta, V., Kim, A., McDorman, K., aFlagella, K., Venook, R., Ross, S., Spencer, S. D., Wong, W. L., Lowman, H. B., Vandlen, R., Sliwkowski, M. X., Scheller, R. H., Polakis, P., and Mallet, W. (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index Nat. Biotechnol. 26, 925-932
18. Sznol, M., Hamid, O., Hwu, P., Kluger, H., Hawthorne, T., Crowley, E., Simantov, R., and Pavlick, A. (2009) Pharmacokinetics of CR011-vcMMAE, an antibody-drug conjugate, in a phase I study of patients with advanced melanoma ASCO Meetings Abtracts 2009, 9063
19. Boswell, C. A., Mundo, E. E., Zhang, C., Bumbaca, D., Valle, N. R., Kozak, K. R., Fourie, A., Chuh, J., Koppada, N., Saad, O., Gill, H., Shen, B. Q., Rubinfeld, B., Tibbitts, J., Kaur, S., Theil, F. P., Fielder, P. J., Khawli, L. A., and Lin, K. (2011) Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-steap1 antibody-drug conjugates in rats Bioconjugate Chem. 22, 1994-2004
20. Stephan, J. P., Chan, P., Lee, C., Nelson, C., Elliott, J. M., Bechtel, C., Raab, H., Xie, D., Akutagawa, J., Baudys, J., Saad, O., Prabhu, S., Wong, W. L., Vandlen, R., Jacobson, F., and Ebens, A. (2008) Anti-CD22-MCC-DM1 and MC-MMAF conjugates: Impact of assay format on pharmacokinetic parameters determination Bioconjugate Chem. 19, 1673-1683
21. Riechmann, L., Clark, M., Waldmann, H., and Winter, G. (1988) Reshaping human antibodies for therapy Nature 332, 323-327
22. Foote, J. and Winter, G. (1992) Antibody framework residues affecting the conformation of the hypervariable loops J. Mol. Biol. 224, 487-499
23. Hongo, J. A., Mora-Worms, M., Lucas, C., and Fendly, B. M. (1995) Development and characterization of murine monoclonal antibodies to the latency-associated peptide of transforming growth factor h 1 Hybridoma 14, 253-260
24. Polson, A. G., Zheng, B., Elkins, K., Chang, W., Du, C., Dowd, P., Yen, L., Tan, C., Hongo, J. A., Koeppen, H., and Ebens, A. (2006) Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia Int. Immunol. 18, 1363-1373
25. Wakankar, A. A., Feeney, M. B., Rivera, J., Chen, Y., Kim, M., Sharma, V. K., and Wang, Y. J. (2010) Physicochemical Stability of the Antibody-Drug Conjugate Trastuzumab-DM1: Changes due to Modification and Conjugation Processes Bioconjugate Chem. 21, 1588-1595